CR9415A - Uso de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico (egfr) en pacientes resistentes al gefitinib - Google Patents

Uso de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico (egfr) en pacientes resistentes al gefitinib

Info

Publication number
CR9415A
CR9415A CR9415A CR9415A CR9415A CR 9415 A CR9415 A CR 9415A CR 9415 A CR9415 A CR 9415A CR 9415 A CR9415 A CR 9415A CR 9415 A CR9415 A CR 9415A
Authority
CR
Costa Rica
Prior art keywords
egfr
inhibitor
ephermal
growth factor
resistant patients
Prior art date
Application number
CR9415A
Other languages
English (en)
Inventor
Charles M Zacharchuk
Susan E Quinn
Patricia Martins
Lee Greenberger
Ante Bill Lundberg
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR9415A publication Critical patent/CR9415A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invencion describe un metodo para tratar o inhibir el cancer en un humano que tiene al menos uno de un E746-A750 eliminacion de exon 19 y/o una mutacion de punto exon 21 que comprende administrar a dicho humano gefitinib y/o iressa solo o en combinacion con otros agentes citotoxicos o agentes quimioterapeuticos y una cantidad efectiva del inhibidor de cinasa EGFR.
CR9415A 2005-04-14 2007-10-04 Uso de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico (egfr) en pacientes resistentes al gefitinib CR9415A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67128705P 2005-04-14 2005-04-14

Publications (1)

Publication Number Publication Date
CR9415A true CR9415A (es) 2008-01-21

Family

ID=36791648

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9415A CR9415A (es) 2005-04-14 2007-10-04 Uso de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico (egfr) en pacientes resistentes al gefitinib

Country Status (19)

Country Link
US (1) US20060235046A1 (es)
EP (1) EP1871371A2 (es)
JP (1) JP2008536847A (es)
KR (1) KR20080002826A (es)
CN (1) CN101160129A (es)
AR (1) AR053357A1 (es)
AU (1) AU2006236940A1 (es)
BR (1) BRPI0610574A2 (es)
CA (1) CA2646257A1 (es)
CR (1) CR9415A (es)
GT (1) GT200600146A (es)
IL (1) IL186302A0 (es)
MX (1) MX2007012662A (es)
NO (1) NO20074722L (es)
PE (1) PE20061396A1 (es)
RU (1) RU2007134908A (es)
TW (1) TW200718421A (es)
WO (1) WO2006113151A2 (es)
ZA (1) ZA200708755B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101313702B1 (ko) 2005-02-03 2013-10-04 와이어쓰 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
EP1942937A1 (en) * 2005-11-04 2008-07-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
BRPI0914790A2 (pt) 2008-06-17 2015-10-20 Wyeth Llc uso de um composto de vinorelbina e um composto de hki-272, composição farmacêutica e produto e kit para o tratamento de neoplasma
US8669273B2 (en) * 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
JP2012501654A (ja) * 2008-09-05 2012-01-26 アビラ セラピューティクス， インコーポレイテッド 不可逆的インヒビターの設計のためのアルゴリズム
WO2010086382A1 (en) * 2009-01-30 2010-08-05 Pronota N.V. Target for treatment of acute heart failure
DK3000467T3 (da) 2009-04-06 2023-03-27 Wyeth Llc Behandling med neratinib mod brystkræft
US9556426B2 (en) 2009-09-16 2017-01-31 Celgene Avilomics Research, Inc. Protein kinase conjugates and inhibitors
JP2013516422A (ja) 2009-12-30 2013-05-13 アビラ セラピューティクス， インコーポレイテッド タンパク質のリガンド−指向性共有的修飾
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
US9364469B1 (en) * 2015-08-26 2016-06-14 Macau University Of Science And Technology Identification of a new AMPK activator for treatment of lung cancer
EA202190749A1 (ru) 2018-09-10 2021-07-09 Мирати Терапьютикс, Инк. Способы комбинированной терапии

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
WO2005018677A2 (en) * 2003-08-01 2005-03-03 Wyeth Holdings Corporation Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer
US7399865B2 (en) * 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
ES2425749T3 (es) * 2004-03-31 2013-10-17 The General Hospital Corporation Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico
KR101313702B1 (ko) * 2005-02-03 2013-10-04 와이어쓰 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물

Also Published As

Publication number Publication date
PE20061396A1 (es) 2007-01-12
ZA200708755B (en) 2008-10-29
GT200600146A (es) 2006-11-07
BRPI0610574A2 (pt) 2010-07-06
AU2006236940A1 (en) 2006-10-26
WO2006113151A3 (en) 2007-01-11
IL186302A0 (en) 2008-08-07
MX2007012662A (es) 2008-04-04
CN101160129A (zh) 2008-04-09
KR20080002826A (ko) 2008-01-04
RU2007134908A (ru) 2009-05-20
CA2646257A1 (en) 2006-10-26
TW200718421A (en) 2007-05-16
JP2008536847A (ja) 2008-09-11
EP1871371A2 (en) 2008-01-02
NO20074722L (no) 2007-11-12
WO2006113151A2 (en) 2006-10-26
AR053357A1 (es) 2007-05-02
US20060235046A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
CR9415A (es) Uso de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico (egfr) en pacientes resistentes al gefitinib
ECSP066341A (es) Uso de una combinación de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico y agentes citotóxicos para el tratamiento e inhibición del cáncer
PA8637301A1 (es) Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la b-secretasa
AR048819A1 (es) Metodos sinergicos y composiciones para el tratamiento del cancer
ECSP077401A (es) Medicamentos que contienen compuestos de carbonilo y su uso
CL2007003523A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
TNSN08375A1 (en) Quinazolines for pdk1 inhibition
IL184617A (en) Antibody against dr5 that includes mutations in the heavy and light chain of the full-length antibody 16e2 and various aspects related to this antibody
IL175714A0 (en) Quinazolinone compounds as anticancer agents
CL2007003244A1 (es) Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CY1108843T1 (el) 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων
ECSP088619A (es) Combinación de un inhibidor de acetilcolinesterasa y un antagonista de 5-ht6 para el tratamiento de la disfunción cognitiva
WO2008063558A3 (en) Combination of an inhibitor of dna polymerase-alpha and an inhibitor of a checkpoint kinase for proliferative disorders
SV2006002342A (es) Terapia de antiogenesis para enfermedades autoinmunes en pacientes que tuvieron la terapia anterior interrumpida
ZA200801332B (en) Pentacyclic kinase inhibitors
MXPA05011858A (es) Agentes terapeuticos que comprenden un agente antiagiongenico en combinacion con un inhibidor src y su uso terapeutico.
SG161281A1 (en) Hgf beta chain variants
IL162862A0 (en) Short-acting sedative hypnotic agents for anesthesia and sedation
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
BRPI0515721A (pt) uso de um inibidor de src cinase e um inibidor de bcr-abl, composição farmacêutica e combinação
EP1961447A3 (en) Treating depressive disorders with PKC activators
WO2007120333A3 (en) Tetracyclic kinase inhibitors
IL187408A0 (en) Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases
BRPI0511475A (pt) combinação, composição farmacêutica, uso de uma combinação, e, método para o tratamento de cáncer
PL1838716T3 (pl) Dihydrat embonianu olanzapiny

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)